<br />
European Edition<br />
HEMATOLOGY<br />
Suppl. 1 April 2020 emjreviews.com<br />
+ EHA 2019<br />
Practical Insights into<br />
Managing Follicular<br />
Lymphoma: What’s<br />
Best for Patients?<br />
Practical Insights into Managing Follicular<br />
Lymphoma: What’s Best for Patients?<br />
This satellite symposium took place on Thursday 13th June 2019 as<br />
part of the 24th European Hematology Association (EHA) Congress in<br />
Amsterdam, the Netherlands<br />
Chairperson: Judith Trotman1<br />
Speakers: Miguel Canales,2 Wendy Osborne,3 Martin Dreyling4<br />
1. Concord Repatriation General Hospital, University of Sydney, Sydney, Australia<br />
2. La Paz University Hospital, Madrid, Spain<br />
3. Freeman Hospital, Newcastle upon Tyne, UK<br />
4. University Hospital Grosshadern, Ludwig Maximilan University of Munich, Munich,<br />
Germany<br />
Disclosure: Pro<a title="EMJ Hematology. 2020 Suppl 1 page 1" href="http://viewer.zmags.com/publication/246e4b67?page=1"> European Edition HEMATOLOGY Suppl. 1 April 20</a>
<a title="EMJ Hematology. 2020 Suppl 1 page 2" href="http://viewer.zmags.com/publication/246e4b67?page=2"> Practical Insights into Managing Follicular L</a>
<a title="EMJ Hematology. 2020 Suppl 1 page 3" href="http://viewer.zmags.com/publication/246e4b67?page=3"> with R-bendamustine. The need for adequate prophy</a>
<a title="EMJ Hematology. 2020 Suppl 1 page 4" href="http://viewer.zmags.com/publication/246e4b67?page=4"> had a 10-year estimated mortality rate of 4% comp</a>
<a title="EMJ Hematology. 2020 Suppl 1 page 5" href="http://viewer.zmags.com/publication/246e4b67?page=5"> Figure 1: Progression-free survival and time to n</a>
<a title="EMJ Hematology. 2020 Suppl 1 page 6" href="http://viewer.zmags.com/publication/246e4b67?page=6"> Prof Canales gave this patient G-CHOP; during his</a>
<a title="EMJ Hematology. 2020 Suppl 1 page 7" href="http://viewer.zmags.com/publication/246e4b67?page=7"> In the panel discussion about bendamustine, Prof </a>
<a title="EMJ Hematology. 2020 Suppl 1 page 8" href="http://viewer.zmags.com/publication/246e4b67?page=8"> in the maintenance period as a direct result of T</a>
<a title="EMJ Hematology. 2020 Suppl 1 page 9" href="http://viewer.zmags.com/publication/246e4b67?page=9"> likely to be developed, including gene mutations </a>
<a title="EMJ Hematology. 2020 Suppl 1 page 10" href="http://viewer.zmags.com/publication/246e4b67?page=10"> Figure 3: Overall survival in the follicular lymp</a>
<a title="EMJ Hematology. 2020 Suppl 1 page 11" href="http://viewer.zmags.com/publication/246e4b67?page=11"> rituximab (CHOP-R) as first-line 13. </a>